Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Protalix Biotherapeutics Inc maintains a gross margin of 87.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 62.65%, while the net margin is 54.27%. These profitability ratios, combined with a Return on Equity (ROE) of 27.27%, provide a clear picture of how effectively PLX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PLX competes directly with industry leaders such as ADAG and KRRO. With a market capitalization of $165.98M, it holds a significant position in the sector. When comparing efficiency, PLX's gross margin of 87.77% stands against ADAG's N/A and KRRO's N/A. Such benchmarking helps identify whether Protalix Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.
